Citigroup Inc Rhythm Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 19,992 shares of RYTM stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,992

Previous 190,520 89.51%

Holding current value

$1.03 Million

Previous $8.26 Million 90.07%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$35.41 - $44.37 $6.04 Million - $7.57 Million	-170,528 Reduced 89.51%	19,992 $820,000
Q1 2024 May 10, 2024	BUY	$39.12 - $52.44 $5.33 Million - $7.14 Million	136,220 Added 250.87%	190,520 $8.26 Million
Q4 2023 Feb 09, 2024	SELL	$21.39 - $49.64 $317,513 - $736,856	-14,844 Reduced 21.47%	54,300 $2.5 Million
Q3 2023 Nov 09, 2023	SELL	$15.81 - $27.8 $299,141 - $526,003	-18,921 Reduced 21.49%	69,144 $1.58 Million
Q2 2023 Aug 10, 2023	SELL	$16.32 - $21.15 $4.11 Million - $5.33 Million	-251,890 Reduced 74.1%	88,065 $1.45 Million
Q1 2023 May 11, 2023	BUY	$16.88 - $34.24 $1.09 Million - $2.2 Million	64,394 Added 23.37%	339,955 $6.06 Million
Q4 2022 Feb 09, 2023	BUY	$22.21 - $30.25 $74,936 - $102,063	3,374 Added 1.24%	275,561 $8.02 Million
Q3 2022 Nov 10, 2022	BUY	$4.3 - $30.85 $1.16 Million - $8.33 Million	269,921 Added 11911.78%	272,187 $6.67 Million
Q2 2022 Aug 10, 2022	SELL	$3.12 - $12.25 $7,069 - $27,758	-2,266 Reduced 50.0%	2,266 $9,000
Q1 2022 May 12, 2022	SELL	$6.13 - $12.24 $560,803 - $1.12 Million	-91,485 Reduced 95.28%	4,532 $52,000
Q4 2021 Feb 10, 2022	BUY	$8.62 - $13.9 $312,828 - $504,444	36,291 Added 60.76%	96,017 $958,000
Q3 2021 Nov 10, 2021	BUY	$11.68 - $20.72 $697,599 - $1.24 Million	59,726 New	59,726 $780,000

Others Institutions Holding RYTM

# of Institutions

178

Shares Held

69.1M

Call Options Held

467K

Put Options Held

224K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $2.86B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account